You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
UCSF's test, developed with Mammoth Biosciences, uses CRISPR technology, while the tests from the Broad Institute and BioSewoom are PCR-based.
The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
Sherlock Bio recently received US Food and Drug Administration Emergency Use Authorization for the kit, which uses CRISPR to detect the virus in patient samples.
In a study published last month, Mammoth demonstrated the technology's sensitivity, specificity, and speed compared to PCR-based COVID-19 testing.
The company said its test, which provides results in approximately one hour, is the first instance of CRISPR technology being authorized by the FDA.